Guillermo Garcia-Manero, MD
M.D. Anderson Cancer Center · MD Anderson · UT MD Anderson Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Registry trials as an overall official
22
all conditions, ClinicalTrials.gov
NIH grants tied to them
0
NIH RePORTER
Trial papers
0
PubMed author-name match
Trials
Studies that name Guillermo Garcia-Manero, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:20 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT05732103 · A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic SyndromesChordia Therapeutics, Inc. · recruiting · Acute Myeloid Leukemia, Myelodysplastic Syndromes · principal investigator
- Ph3NCT03151408 · An Efficacy and Safety Study Of Pracinostat In Combination With Azacitidine In Adults With Acute Myeloid LeukemiaHelsinn Healthcare SA · terminated · Acute Myeloid Leukemia · study chair
- Ph2NCT02599649 · Lirilumab and Nivolumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS)M.D. Anderson Cancer Center · terminated · Leukemia · principal investigator
- N/ANCT02378701 · Interventional Validation of an MDS-Specific Measure of Quality of Life: Assessing the Responsiveness of the Quality of Life in Myelodysplasia Scale (QUALMS-1) to Different Hypomethylating Agent Regimens for Low and Intermediate Risk DiseaseM.D. Anderson Cancer Center · completed · Leukemia · principal investigator
- Ph1/Ph2NCT02363491 · A Phase I/II Study of OPN-305 in Second-line Lower Risk Myelodysplastic SyndromeOpsona Therapeutics Ltd. · completed · Myelodysplastic Syndrome
- Ph1/Ph2NCT02193958 · Study of FF-10501-01 in Patients With Relapsed or Refractory Hematological MalignanciesFujifilm Pharmaceuticals U.S.A., Inc. · completed · AML, CMML, MDS · principal investigator
- Ph2NCT01993641 · Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMAHelsinn Healthcare SA · completed · Myelodysplastic Syndrome, MDS · principal investigator
- Ph2NCT01912274 · Safety and Efficacy Study of Pracinostat With Azacitadine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)Helsinn Healthcare SA · completed · Acute Myeloid Leukemia · principal investigator
- Ph1NCT01895842 · Ruxolitinib for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)M.D. Anderson Cancer Center · completed · Leukemia · principal investigator
- Ph2NCT01891968 · Bortezomib for Low or Intermediate-1 Myelodysplastic Syndrome (MDS) With p65 ActivationM.D. Anderson Cancer Center · completed · Leukemia · principal investigator
- Ph2NCT01873703 · Phase 2 Study of Pracinostat With Azacitidine in Patients With Previously Untreated Myelodysplastic SyndromeHelsinn Healthcare SA · completed · Myelodysplastic Syndrome · principal investigator
- Ph1NCT01684150 · A Phase 1, Open-Label, Dose-Escalation & Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK & PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias InvolvingEpizyme, Inc. · completed · Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome · principal investigator
- Ph2NCT01444742 · Clofarabine Plus Low-Dose Cytarabine for Patients With Higher-Risk Myelodysplastic Syndrome (MDS)M.D. Anderson Cancer Center · completed · Leukemia, Myeloproliferative Diseases · principal investigator
- Ph2NCT01436084 · SB1518 for Patients With Myelodysplastic Syndrome (MDS)M.D. Anderson Cancer Center · terminated · Leukemia · principal investigator
- Ph1/Ph2NCT01038635 · 5-Azacytidine With Lenalidomide in Patients With High Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)M.D. Anderson Cancer Center · completed · Leukemia · study chair
- Ph2NCT00948064 · Vorinostat in Combination With Azacitidine in Patients With Newly-Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)M.D. Anderson Cancer Center · completed · Leukemia · principal investigator
- Ph2NCT00939159 · Study of LBH589 for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)M.D. Anderson Cancer Center · terminated · Myelodysplastic Syndrome · study chair
- Ph2NCT00893997 · PR1 Vaccination in Myelodysplastic Syndrome (MDS)M.D. Anderson Cancer Center · terminated · Leukemia, Myelodysplastic Syndrome · principal investigator
- Ph1NCT00741234 · A Phase I Dose Escalation Study of Oral SB939 Administered Alone or With AzacitidineS*BIO · completed · Solid Tumors, Hematologic Malignancies, Myelodysplastic Syndrome · principal investigator
- Ph2NCT00382590 · Azacytidine With Valproic Acid Versus Ara-C in Acute Myeloid Leukemia (AML)/ Myelodysplastic Syndrome (MDS) PatientsM.D. Anderson Cancer Center · completed · Acute Myelogenous Leukemia, Myelodysplastic Syndrome, Leukemia · principal investigator
- Ph1NCT00349596 · A Study of Low-Dose Decitabine in Relapsed or Refractory Acute Lymphocytic Leukemia (ALL)M.D. Anderson Cancer Center · completed · Acute Lymphocytic Leukemia · principal investigator
- Ph2NCT00326170 · Phase II 5-Azacytidine Plus VPA Plus ATRAM.D. Anderson Cancer Center · completed · Myelodysplastic Syndrome, Acute Myelogenous Leukemia · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:20 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.